Are patients with rheumatologic diseases on chronic immunosuppressive therapy at lower risk of developing severe symptoms when infected with COVID-19?
作者信息
Vakil-Gilani Kiana, O'Rourke Kenneth
机构信息
Department of Rheumatology, Maine Medical Center, Portland, ME, USA.
出版信息
Clin Rheumatol. 2020 Jul;39(7):2067-2068. doi: 10.1007/s10067-020-05184-3. Epub 2020 May 30.
Abstract
摘要
相似文献
1
Are patients with rheumatologic diseases on chronic immunosuppressive therapy at lower risk of developing severe symptoms when infected with COVID-19?接受慢性免疫抑制治疗的风湿性疾病患者在感染新型冠状病毒肺炎时出现严重症状的风险较低吗？
Clin Rheumatol. 2020 Jul;39(7):2067-2068. doi: 10.1007/s10067-020-05184-3. Epub 2020 May 30.
2
COVID-19 and rheumatology: is shielding really necessary?新型冠状病毒肺炎与风湿病学：真的有必要进行防护吗？
Br J Hosp Med (Lond). 2020 Jun 2;81(6):1-3. doi: 10.12968/hmed.2020.0284. Epub 2020 Jun 3.
3
No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic.在SARS-CoV-2大流行期间，接受IL-6R抑制剂治疗的意大利风湿病患者出现呼吸道症状的风险并不更高。
Rheumatology (Oxford). 2020 Sep 1;59(9):2644-2646. doi: 10.1093/rheumatology/keaa388.
4
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.如何在 COVID-19 时代处理自身免疫性风湿和炎症性肠病患者：专家意见。
Autoimmun Rev. 2020 Jul;19(7):102574. doi: 10.1016/j.autrev.2020.102574. Epub 2020 May 5.
5
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.德国炎症性风湿病（IRD）患者感染 SARS-CoV-2 的国家登记处（ReCoVery）：了解 IRD 患者 SARS-CoV-2 感染临床病程的快速可靠知识的宝贵手段。
RMD Open. 2020 Sep;6(2). doi: 10.1136/rmdopen-2020-001332.
6
How to manage rheumatic patients during the coronavirus pandemic.如何在新冠疫情期间管理风湿病患者。
Panminerva Med. 2020 Sep;62(3):176-177. doi: 10.23736/S0031-0808.20.03935-X. Epub 2020 Apr 28.
7
[Current guidance of the German Society of Rheumatology for the care of patients with rheumatic diseases during the SARS-CoV-2/Covid 19 pandemic].[德国风湿病学会关于SARS-CoV-2/新冠疫情期间风湿病患者护理的当前指南]
Z Rheumatol. 2020 May;79(4):385-388. doi: 10.1007/s00393-020-00799-y.
8
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.一组患有风湿性疾病的COVID-19患者的临床病程、严重程度和死亡率。
Ann Rheum Dis. 2020 Dec;79(12):1659-1661. doi: 10.1136/annrheumdis-2020-218054. Epub 2020 Jun 30.
9
COVID-19 and smoking: a high-risk association.新型冠状病毒肺炎与吸烟：一种高风险关联。
Cad Saude Publica. 2020;36(5):e00072020. doi: 10.1590/0102-311x00072020. Epub 2020 May 18.
10
Covid-19 and Kidney Transplantation.新冠病毒-19与肾移植
N Engl J Med. 2020 Jun 18;382(25):2475-2477. doi: 10.1056/NEJMc2011117. Epub 2020 Apr 24.
引用本文的文献
1
Protein Posttranslational Signatures Identified in COVID-19 Patient Plasma.在新冠肺炎患者血浆中鉴定出的蛋白质翻译后特征。
Front Cell Dev Biol. 2022 Feb 11;10:807149. doi: 10.3389/fcell.2022.807149. eCollection 2022.
2
Neuromuscular Diseases Care in the Era of COVID-19.新冠疫情时代的神经肌肉疾病护理
Front Neurol. 2020 Nov 26;11:588929. doi: 10.3389/fneur.2020.588929. eCollection 2020.
本文引用的文献
1
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.免疫介导性炎症疾病中的新冠病毒病——来自纽约的病例系列
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
2
Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.风湿病学家对 2019 冠状病毒病（COVID-19）的看法和潜在治疗靶点。
Clin Rheumatol. 2020 Jul;39(7):2055-2062. doi: 10.1007/s10067-020-05073-9. Epub 2020 Apr 10.
3
Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.表观遗传调控 ACE2 和干扰素调节基因可能提示狼疮患者 COVID-19 的易感性和严重程度增加。
Clin Immunol. 2020 Jun;215:108410. doi: 10.1016/j.clim.2020.108410. Epub 2020 Apr 8.
4
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.新型冠状病毒肺炎患者的凝血障碍与抗磷脂抗体
N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.
5
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.生物制剂治疗的风湿性疾病合并冠状病毒感染的推荐建议。
J Autoimmun. 2020 May;109:102442. doi: 10.1016/j.jaut.2020.102442. Epub 2020 Apr 2.
6
Baricitinib for COVID-19: a suitable treatment?巴瑞替尼用于治疗新冠肺炎：一种合适的治疗方法？
Lancet Infect Dis. 2020 Sep;20(9):1012-1013. doi: 10.1016/S1473-3099(20)30262-0. Epub 2020 Apr 3.
7
The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic.COVID-19 全球风湿病联盟：大流行期间的数据收集。
Nat Rev Rheumatol. 2020 Jun;16(6):293-294. doi: 10.1038/s41584-020-0418-0.
8
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.一系列接受免疫抑制靶向治疗的慢性关节炎患者的 COVID-19 临床病程。
Ann Rheum Dis. 2020 May;79(5):667-668. doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2.
9
Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic.冠状病毒与免疫抑制患者：第三次疫情期间的实际情况
Liver Transpl. 2020 Jun;26(6):832-834. doi: 10.1002/lt.25756. Epub 2020 Apr 24.
10
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
Zotero 插件